TY - JOUR
T1 - Biological Pathways of Long-Term Visit-to-Visit Blood Pressure Variability in the American Population
T2 - Cardiovascular Health Study and Women's Health Initiatives
AU - Faramawi, Mohammed F.
AU - Orloff, Mohammed S.
AU - Delongchamp, Robert
AU - Wang, Yan
AU - Feingold, Eleanor
AU - Thapa, Susan
AU - Jin, Jing
AU - Delhey, Leanna
AU - Abouelenein, Saly
AU - Zhang, Qing
AU - Singh, Karan P.
N1 - Funding Information:
Studies reported a positive relationship between visit-to-visit blood pressure variability (VVBPV) and cardiovascular morbidity and mortality independently of the mean arterial blood pressure across clinical visits. The literature is scarce on the genes and biological mechanisms that regulate long-term VVBPV. We sought to identify biological pathways that regulate visit-to-visit blood pressure variability. We used phenotypic and genotype data from the Women’s Health Initiatives and Cardiovascular Health Studies. We defined VVBPV of systolic and diastolic blood pressure phenotypes as the standard deviation about the participant’s regression line with systolic and diastolic blood pressure regressed separately across visits. We imputed missing genotypes and then conducted a genome-wide association analysis to identify genomic variants related to the VVBPV and detect biological pathways. For systolic VVBPV, we identified a neurological pathway, the GABAergic pathway ( P values = 1.1 E − 2), and a vascular pathway, the RAP1 signaling pathway ( P values = 5.8 E − 2). For diastolic VVBPV, the hippo signaling ( P values = 4.1 E − 2), CDO myogenesis ( P values = 7.0 E − 2), and O-glycosylation of TSR domain-containing protein pathways ( P values = 9.0 E − 2) were the significant pathways. Future studies are warranted to validate these results. Further understanding of the roles of the genes regulating the identified pathways will help researchers to improve future pharmacological interventions to treat VVBPV in clinical practice. National Heart, Lung, and Blood Institute National Institutes of Health 1R15HL126074-01A1 National Science Foundation CNS-0855248 EPS-0701890 EPS-0918970 CNS-0619069 OISE-0729792 National Center for Research Resources P20RR016460 National Institute of General Medical Sciences P20 GM103429 U.S. Department of Health and Human Services
Publisher Copyright:
© 2020 Mohammed F. Faramawi et al.
PY - 2020
Y1 - 2020
N2 - Studies reported a positive relationship between visit-to-visit blood pressure variability (VVBPV) and cardiovascular morbidity and mortality independently of the mean arterial blood pressure across clinical visits. The literature is scarce on the genes and biological mechanisms that regulate long-term VVBPV. We sought to identify biological pathways that regulate visit-to-visit blood pressure variability. We used phenotypic and genotype data from the Women's Health Initiatives and Cardiovascular Health Studies. We defined VVBPV of systolic and diastolic blood pressure phenotypes as the standard deviation about the participant's regression line with systolic and diastolic blood pressure regressed separately across visits. We imputed missing genotypes and then conducted a genome-wide association analysis to identify genomic variants related to the VVBPV and detect biological pathways. For systolic VVBPV, we identified a neurological pathway, the GABAergic pathway (P values = 1.1E-2), and a vascular pathway, the RAP1 signaling pathway (P values = 5.8E-2). For diastolic VVBPV, the hippo signaling (P values = 4.1E-2), CDO myogenesis (P values = 7.0E-2), and O-glycosylation of TSR domain-containing protein pathways (P values = 9.0E-2) were the significant pathways. Future studies are warranted to validate these results. Further understanding of the roles of the genes regulating the identified pathways will help researchers to improve future pharmacological interventions to treat VVBPV in clinical practice.
AB - Studies reported a positive relationship between visit-to-visit blood pressure variability (VVBPV) and cardiovascular morbidity and mortality independently of the mean arterial blood pressure across clinical visits. The literature is scarce on the genes and biological mechanisms that regulate long-term VVBPV. We sought to identify biological pathways that regulate visit-to-visit blood pressure variability. We used phenotypic and genotype data from the Women's Health Initiatives and Cardiovascular Health Studies. We defined VVBPV of systolic and diastolic blood pressure phenotypes as the standard deviation about the participant's regression line with systolic and diastolic blood pressure regressed separately across visits. We imputed missing genotypes and then conducted a genome-wide association analysis to identify genomic variants related to the VVBPV and detect biological pathways. For systolic VVBPV, we identified a neurological pathway, the GABAergic pathway (P values = 1.1E-2), and a vascular pathway, the RAP1 signaling pathway (P values = 5.8E-2). For diastolic VVBPV, the hippo signaling (P values = 4.1E-2), CDO myogenesis (P values = 7.0E-2), and O-glycosylation of TSR domain-containing protein pathways (P values = 9.0E-2) were the significant pathways. Future studies are warranted to validate these results. Further understanding of the roles of the genes regulating the identified pathways will help researchers to improve future pharmacological interventions to treat VVBPV in clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=85083175575&partnerID=8YFLogxK
U2 - 10.1155/2020/3841945
DO - 10.1155/2020/3841945
M3 - Article
AN - SCOPUS:85083175575
VL - 2020
JO - BioMed Research International
JF - BioMed Research International
SN - 2314-6133
M1 - 3841945
ER -